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Abstract 
 
Objective Inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis 
(UC), are multifactorial disorders, characterized by chronic inflammation of the intestine. A 
number of genetic components have been proposed to contribute to IBD pathogenesis. In 
this case-control study, we investigated the association between two common vitamin D-
binding protein (DBP) genetic variants and IBD susceptibility. These two single nucleotide 
polymorphisms in exon 11 of the DBP gene, at codons 416 (GAT>GAG; Asp>Glu) and 420 
(ACG>AAG; Thr>Lys), have previously been suggested to play roles in the etiology of other 
autoimmune diseases. 
 
Methods Using TaqMan SNP technology, we have genotyped 884 individuals (636 IBD 
cases and 248 non-IBD controls) for the two DBP variants. 
 
Results Upon statistical analysis, we observed that the DBP 420 variant Lys is less 
frequent in IBD cases than in non-IBD controls (allele frequencies, p=0.034; homozygous 
carrier genotype frequencies, p=0.006). This inverse association between the DBP 420 Lys 
and the disease remained significant, when non-IBD subjects were compared with UC 
(homozygous carrier genotype frequencies, p=0.022) or CD (homozygous carrier genotype 
frequencies, p=0.016) patients separately. While the DBP position 416 alone was not found 
to be significantly associated with IBD, the haplotype DBP_2, consisting of 416 Asp and 
420 Lys, was more frequent in the non-IBD population, particularly notably when compared 
to the UC group (OR 4.390). 
 
Conclusion Our study adds DBP to the list of potential genes that contribute to the complex 
genetic etiology of IBD, and further emphasizes the association between vitamin D 
homeostasis and intestinal inflammation. 
 
Key words: 
Inflammatory bowel disease, vitamin D-binding protein, Crohn’s disease, ulcerative colitis, 
vitamin D homeostasis 
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Introduction 
 
The biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 (vitamin D3) controls the 
serum calcium concentration and overall calcium homeostasis, and low vitamin D3 levels 
result in acceleration of bone turnover. Furthermore, vitamin D3 contributes to 
immunomodulation and possesses antiproliferative properties [1]. In the intestine, vitamin 
D3 has additional important functions, such as promotion of the integrity of mucosal tight 
junctions [2], enhancement of epithelial folate absorption [3], and activation of intestinal 
cytochrome P450 3A4 expression [4]. 
 
Vitamin D-binding protein (DBP) is a multifunctional glycosylated protein, encoded by the 
GC (gc-globulin = group-specific component) gene on chromosome 4 in humans [5-9, and 
references therein]. It belongs to the albumin multigene cluster family of proteins, together 
with -fetoprotein and albumin itself. DBP is synthesized predominantly in liver 
parenchymal cells, as a precursor form of 474 amino acids, which is processed to the 
mature form of 458 amino acids (~58 kDa). The primary structure of DBP contains 28 
cysteine residues, which can form multiple disulfide bonds. DBP primarily locates in 
circulating plasma at the concentration of ~5 M, but can also be found in ascitic and 
cerebrospinal fluids, and in cytoplasm of nucleated cells, as well as surface membranes of 
B and T lymphocytes. In plasma, DBP mediates vitamin D metabolite transport and fatty 
acid transport to target tissues. Additional reported functions of DBP include inhibition of 
actin polymerization and macrophage activation.  
 
The DBP gene in humans exists as three common variants, and over 100 rare variants [9]. 
The three major DBP isoforms are referred to as Gc1F (wild-type), Gc1S, and Gc2. All 
three isoforms exhibit comparable chemotactic activity [10], but the total levels of DBP in 
circulation appear to be determined by the Gc phenotype [11]. The isotypes are 
distinguished by distinct combinations of substitutions at amino acid positions 416 
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(Asp>Glu) and 420 (Lys>Thr). Relative to the wild-type Gc1F protein, the Gc1s is defined 
by containing the Asp416Glu polymorphism, and the Gc2 contains the Thr420Lys 
polymorphism. Enzymatic processing of the DBP O-linked carbohydrate to GalNac results 
in the transformation of the DBP molecules into the macrophage-activating factors (MAF). 
MAF is a lymphokine that primes macrophages, when required during the host defence 
responses in infectious and inflammatory diseases and against tumours [12]. Furthermore, 
MAF can induce macrophage cell death by enhancing caspase activity at sites of infection 
or inflammation [13]. 
 
Several studies have proposed a link between genetic variants of DBP and disease in 
humans. These include many conditions of suspected autoimmune etiology, such as 
Graves’ disease, diabetes, and osteoporosis [reviewed in 9]. Inflammatory bowel disease 
(IBD) is a condition characterized by recurrent inflammation of the intestinal mucosa, and is 
caused by deranged function of mucosal immune system in genetically susceptible 
subjects [reviewed in 14]. IBD etiology clearly involves a complex interaction of genetic, 
environmental, and immunomodulatory factors. Two major forms of IBD exist. In Crohn’s 
disease (CD), the entire gastrointestinal tract may be affected, although the most frequent 
site of inflammation is the ileum, whereas in ulcerative colitis (UC) the inflammation 
typically affects the colon. In CD pathogenesis, a strong genetic component has been 
suggested by the concordance of 63.6% in monozygotic twins, but only of 3.6% in dizygotic 
ones. In UC, the concordance of monozygotic twins is lower (6%), implying that genetic 
factors may play a somewhat smaller role in this disease [15]. IBD is more prevalent in 
northern Europe and North America, where less vitamin D is synthesized in the skin upon 
lower exposure to sunlight [16]. Vitamin D deficiency also frequently occurs in IBD patients, 
even when the disease itself may be in a state of remission [17]. 
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Genetic variants of the nuclear receptor for vitamin D3, VDR, the chief executor of vitamin 
D3 actions within cell nuclei, have previously been suggested to be associated with 
inflammatory bowel disease (IBD) [18,19]. Here, we have studied whether two common 
variants of the other important player in vitamin D homeostasis, DBP, are associated with 
IBD and its subtypes UC and CD. 
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Materials and methods 
 
Study subjects 
The study population was Swiss, and comprised of 248 healthy subjects and 636 IBD 
patients, from which 232 were diagnosed to suffer from UC and 404 from CD. The IBD 
subjects were recruited at the centers participating in the Swiss Inflammatory Bowel Disease 
Cohort Study (SIBDCS) [20]. For the IBD patients, the diagnosis of UC or CD was confirmed 
by the study investigators based on clinical presentation, endoscopic findings, and histology.  
Non-IBD controls were recruited from gastroenterological patients undergoing surveillance 
colonoscopy. History of colorectal cancer was employed as an exclusion criteria for both IBD 
patients and non-IBD control subjects. 
 
DNA extraction 
Genomic DNAs were extracted from either EDTA-blood or intestinal biopsies using the 
QIAamp DNA Mini Kit (QIAGEN, Hombrechtikon, Switzerland) or the TRIzol reagent 
(Invitrogen, Basel, Switzerland), respectively, according to the manufacturer’s instructions. 
 
Genotyping of DBP single nucleotide polymorphisms 
Genotyping of the two DBP SNPs was performed using TaqMan allelic discrimination 
assays. The cycling was performed on an 7900HT Fast Real-Time PCR system (Applied 
Biosystems, Rotkreuz, Switzerland) by using custom-made TaqMan SNP Genotyping 
Assays. The TaqMan primer and probe sequences were as follows: The Asp416Glu 
variant: Left primer, TGGCAGAGCGACTAAAAGCA; right primer, 
CTTGTTAACCAGCTTTGCCAGTTC; VIC-labelled probe AAATTGCCTGATGCCAC; FAM-
labelled probe TTGCCTGAGGCCAC. The Thr420Lys variant: Left primer, 
CGACTAAAAGCAAAATTGCCTGATG; right primer CTGAGTGCTTGTTAACCAGCTTTG; 
VIC-labelled probe CACCCACGGAACTG; FAM-labelled probe CACCCAAGGAACTG. All 
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fluorescent probes had a non-fluorescent quencher at 3’-end. The genomic DNAs were 
quantified with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) and diluted to a final concentration of 10 ng/µl. The amplification run 
conditions were: Once 50°C for 2 min, once 95°C for 10 min, 45 times 95°C for 15 sec and 
60°C for 1 min. 
 
Ethical considerations 
All subjects provided their written informed consent to be included in the study. Ethical 
approvals were obtained from the local medical ethical committees of all study sites 
involved in the Swiss IBD Cohort Study. 
 
Statistical analysis 
Statistical analysis was performed using the software packages SPSS 18 (SPSS Inc., 
Chicago, IL) and GraphPad Prism (GraphPad Software Inc., San Diego, CA). The Chi-
square test or Fisher’s exact test were used to determine associations between individual 
SNPs and subject phenotypes. The PHASE software was used to calculate the haplotypes 
in the DBP gene on the basis of a Bayesian interference algorithm [21]. Linkage 
disequilibrium (LD) was calculated using the r2 statistics. Calculations were performed using 
the software package Haploview (www.haploview.com).  
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Results 
 
 
Study population 
The study population was recruited at centers participating in the Swiss IBD Cohort study 
(SIBDCS). Detailed demographic data of the entire cohort consisting of 884 subjects is 
shown in Table 1. 
 
DBP sequence variability 
The two DBP variants selected for the study are single nucleotide substitutions. The 
genotype frequencies in all groups were in Hardy-Weinberg equilibrium. The obtained allele 
and genotype frequencies are given in Table 2. 
 
Genetic variation in the DBP gene and IBD 
The DBP variant 416 Glu was not found to be significantly associated with the diagnosis of 
IBD, although there was a tendency for this variant to be more common in the IBD 
population than in healthy subjects (Tables 2 and 3). The DBP variant 420 Lys, on the other 
hand, was more common in the healthy population than in the IBD cohort. The minor allele 
frequency was significantly (p=0.034) lower in the IBD population. The level of significance 
became much more notable (p=0.006), when the numbers of carriers of the wild-type 
genotype were compared to the numbers of homozygous SNP carrier in non-IBD and IBD 
populations. Upon subgrouping the IBD patients, the differences in the frequencies of the 
rarer 420 Lys variant remained significant for both UC (p=0.022) and CD (p=0.016). 
Similarly, when adjusted to age and gender, the p values remained significant. 
 
In addition to the two above-mentioned coding DBP SNPs, we also genotyped the study 
population for three DBP promoter SNPs, namely -1424, -944, and -39, previously studied in 
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the context of prostate cancer risk [22]. All the subjects in all subgroups of the current cohort, 
both IBD and non-IBD, were homozygous for the wild-type allele at these three positions 
(data not shown). 
 
DBP haplotypes and IBD 
All individuals, for whom genotype determination could be performed for both DBP variants 
under study were included in the haplotype prediction analysis. Thus, 185 non-IBD subjects, 
225 UC cases and 393 CD cases were included in this analysis. The predicted frequencies 
for all four possible DBP haplotypes are shown in Table 4. The haplotype DBP_2 containing 
the wild-type allele for the position 416 and the rarer allele for the position 420, was 
predicted to be significantly less frequent in the IBD population than in non-IBD subjects 
(p=0.0005) and this inverse association with the disease remained significant when either 
the UC (p=0.0003) or the CD (p=0.013) patients were compared with the non-IBD group 
separately (Table 5). The linkage equilibria between the variants at positions 416 and 420 of 
DBP were moderate (non-IBD controls r2=0.61; IBD cases r2=0.78). 
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Discussion 
 
The etiology of IBD is complex, and a wide range of factors, both genetic and 
environmental, are believed to play roles in IBD pathophysiology. Variants in more than 70 
genes have been identified that may potentially be associated with IBD [23,24]. Many of 
these encode genes that modulate immune responses and antimicrobial defence in the 
intestine, and are thus involved in maintaining the integrity of the intestinal wall epithelium 
[14,23]. Vitamin D metabolites have anti-inflammatory functions, and participate in the 
maintenance of tight junctions between intestinal epithelial cells [2]. While the other major 
player of vitamin D homeostasis, the vitamin D receptor VDR, has previously been 
genetically linked to IBD [18,19], we show here that a common genetic variant of DBP, the 
main transporter of vitamin D to its target tissues in the plasma, is significantly associated 
with IBD. This association is significant in both our UC and CD cohorts. The rarer Lys allele 
at position 420 appears to have a protective role against IBD, as it is more common in 
healthy subjects. The other DBP variant tested 416 Glu did not alone show a significant 
association with IBD, although it exhibited a tendency to be more frequent in IBD cases 
than control subjects, potentially thus acting as a factor contributing to the pathogenesis. 
The haplotype DBP_2, consisting of variants 416 Asp and 420 Lys, was significantly more 
frequent in the non-IBD population, more notably in comparison with the UC (OR 4.390). 
 
Low 25-hydroxyvitamin D3 levels are associated with insulin resistance and metabolic 
syndrome, and genetic variation in codon positions 416 and 420 has previously been 
proposed to be associated with diabetes [25,26], although this association remains 
somewhat controversial [27,28]. Furthermore, the DBP Lys allele at codon 420 has been 
associated with Graves’ disease in a Polish population [29], although in this case the lysine 
was in fact more common in the disease group. This points to potentially differing roles of 
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DBP in the etiologies of IBD and Graves’ disease, even if both represent autoimmune 
disorders. 
 
The exact functional consequences of the amino acid exchanges at positions 416 and 420 
of the DBP protein remain somewhat unclear. This region of the protein is located adjacent 
to the actin-binding domain of DBP (amino acids 350-403), but is more distant from the 
amino-terminal vitamin D-binding domain [30]. In the DBP form carrying the lysine in 
position 420, a major site for O-linked trisaccharide glycosylation is removed [31]. It will be 
of great interest to verify whether the efficiency of vitamin D transport by DBP is affected by 
this amino acid substitution, and in what manner. Given its inverse association with IBD 
reported here, it is perhaps paradoxical that the Gc2 isoform of DBP carrying the lysine in 
codon position 420 has been associated with lower plasma concentrations of vitamin D3 
metabolites than observed for the carriers of the other Gc alleles [11]. It has also been 
shown that the Gc2 isoform has reduced affinity to vitamin D metabolites [32]. We do not at 
this stage understand the exact mechanism by which a DBP isoform that exhibits lower 
affinity to vitamin D exerts a protective effect against IBD, as suggested by our current 
findings. It is conceivable that the reduced affinity could result in enhanced release of 
vitamin D from DBP to the intestinal target tissue that is susceptible to inflammation. 
 
Patients suffering from IBD are frequently on long-term treatment with vitamin D3, in 
addition to calcium, as a prophylaxis against osteoporosis and osteopenia [33]. It will be of 
interest to further explore whether the IBD-associated DBP variants are associated with 
altered clinical response to vitamin D3 supplementation. In conclusion, we have for the first 
time shown an association between a chief component of vitamin D metabolism, DBP, and 
diagnosis of IBD, further supporting the importance of vitamin D homeostasis in this chronic 
inflammatory disease. 
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Table 1. Demographic data of the study population 
 
Total population (N = 884) 
Male                                  404 (45.7%) 
Female                              480 (54.3%) 
Age (Mean +/- SD)            43.0 (+/-15.7) 
Age (Median)                     41 
Age (Minimum)                  16 
Age (Maximum)                 82 
 
Non-IBD (N = 248; 28.1% of total population) 
Male                                   93 (37.5%) 
Female                              155 (62.5%) 
Age (Mean +/- SD)            44.2 (+/- 17.0) 
Age (Median)                     42 
Age (Minimum)                  20 
Age (Maximum)                 81 
 
IBD (UC + CD) (N = 636; 71.9% of total population) 
Male                                  311 (48.9%) 
Female                              325 (51.1%) 
Age (Mean +/- SD)            42.5 (+/- 15.1) 
Age (Median)                     41 
Age (Minimum)                  16 
Age (Maximum)                 82 
 
UC (N = 232; 26.2% of total population) 
Male                                  120 (51.7%)   
Female                              112 (48.3%)        
Age (Mean +/- SD)            45.3 (+/- 15.0) 
Age (Median)                     44 
Age (Minimum)                  18 
Age (Maximum)                 82 
 
CD (N = 404; 45.7% of total population) 
Male                                  191 (47.3%)  
Female                              213 (52.7%)     
Age (Mean +/- SD)            40.8 (+/- 15.0) 
Age (Median)                     39 
Age (Minimum)                  16 
Age (Maximum)                 79 
 
 
Table
Table 2. Determined allele and genotype frequencies for the DBP SNPs Asp416Glu and 
Thr420Lys 
 
Asp416Glu 
Total subjects successfully genotyped: N = 817 (92.4% of total population) 
Male          372 (45.5%) 
Female      445 (54.5%) 
 
Non-IBD    198 (24.2% of total genotyped subjects) 
IBD            619 (75.8% of total genotyped subjects) 
UC      227 (27.8% of total genotyped subjects) 
CD      392 (48.0% of total genotyped subjects) 
 
Minor allele frequencies 
Non-IBD     39.4% 
IBD            42.3%      
UC       44.3% 
CD       41.2% 
 
Genotype frequencies                 WT hom              het              SNP hom 
Non-IBD                              72 (36.4%)      96 (48.5%)      30 (15.2%) 
IBD                                    198 (32.0%)     318 (51.4%)    103 (16.6%) 
UC                                68 (30.0%)      117 (51.5%)     42 (18.5%) 
CD                               130 (33.2%)     201 (51.3%)     61 (15.6%) 
 
 
Thr420Lys 
Total subjects successfully genotyped: N = 827 (93.9% of total population) 
Male          377 (45.6%) 
Female      450 (54.4%) 
 
Non-IBD    197 (23.8% of total genotyped subjects) 
IBD            630 (76.2% of total genotyped subjects) 
UC      228 (27.6% of total genotyped subjects) 
CD      402 (48.6% of total genotyped subjects) 
 
Minor allele frequencies 
Non-IBD     33.0% 
IBD             27.5%      
UC        28.1% 
CD        27.1% 
 
Genotype frequencies               WT hom              het              SNP hom 
Non-IBD                            94 (47.7%)      76 (38.6%)      27 (13.7%) 
IBD                                 330 (52.4%)     254 (40.3%)      46 (7.3%) 
UC                            115 (50.4%)      98 (43.0%)      15 (6.6%) 
CD                            215 (53.5%)    156 (38.8%)      31 (7.7%) 
 
_________________________________________________________________________________ 
WT hom, wild-type homozygote; het, heterozygote; SNP hom, homozygous SNP carrier. 
 
Table
Table 3. Allele and genotype association analysis for the DBP SNPs Asp416Glu and Thr420Lys 
in IBD vs. non-IBD groups 
 
Asp416Glu                                              p                  p’                       OR                   CI 
 
Allele frequencies: 
Non-IBD vs. IBD:                         0.303                                        0.886         0.703-1.116 
 
Genotype frequencies: 
Non-IBD vs. IBD: 
 WT vs. SNP carrier:        0.254             0.319                 1.215          0.869-1.699 
 WT vs. SNP hom:           0.372             0.382                  1.248         0.766-2.034 
 
Thr420Lys                                              p                  p’                       OR                   CI 
 
Allele frequencies: 
Non-IBD vs. IBD:                         0.034*                                       1.301        1.019-1.660 
 
Genotype frequencies: 
Non-IBD vs. IBD: 
 WT vs. SNP carrier:        0.253            0.230                   0.830         0.602-1.143 
 WT vs. SNP hom:           0.006**         0.008**                0.485         0.286-0.822 
Non-IBD vs. UC: 
 WT vs. SNP carrier:       0.576            0.688                    0.897        0.612-1.313 
 WT vs. SNP hom:          0.022*           0.041*                  0.454         0.228-0.903 
Non-IBD vs. CD: 
 WT vs. SNP carrier:       0.185            0.178                    0.794        0.564-1.117 
 WT vs. SNP hom:          0.016*           0.017*                  0.502        0.284-0.888   
 
_______________________________________________________________________________ 
p’, p value adjusted to age and gender; OR, odds ratio; CI, confidence interval. 
  
 
Table
Table 4. Predicted haplotype frequencies for the DBP SNPs Asp416Glu and Thr420Lys in IBD 
vs. non-IBD groups 
 
 Haplotype                                                      Haplotype frequencies                  
                                               non-IBD                  IBD                       UC                    CD 
DBP_1    TC (WT)            198 (53.5%)          683 (55.3%)        245 (54.4%)       438 (55.7%) 
DBP_2    TA                       24 (6.5%)              33 (2.7%)             7 (1.6%)            26 (3.3%) 
DBP_3    GC                      51 (13.8%)          220 (17.8%)          82 (18.2%)       138 (17.6%) 
DBP_4    GA                      97 (26.2%)          300 (24.3%)         116 (25.8%)      184 (23.4%) 
_________________________________________________________________________________ 
The haplotype significantly associated with IBD is underlined 
 
Table
Table 5. Haplotype association analysis for the DBP SNPs Asp416Glu and Thr420Lys in IBD vs. 
non-IBD groups 
 
     Haplotype                                        p                           OR                           CI           
DBP_1 TC (WT) 
 Non-IBD vs. IBD                   0.549                       0.931                   0.738-1.175 
DBP_2 TA 
 Non-IBD vs. IBD                   0.0005***                2.529                    1.475-4.336 
 Non-IBD vs. UC                    0.0003***               4.390                    1.869-10.31 
 Non-IBD vs. CD                    0.013*                    2.028                    1.147-3.583 
DBP_3 GC 
 Non-IBD vs. IBD                   0.068                      0.737                   0.530-1.024 
DBP_4 GA 
 Non-IBD vs. IBD                   0.417                      1.116                   0.856-1.454 
__________________________________________________________________________________ 
The haplotype significantly associated with IBD is underlined. 
OR, odds ratio; CI, confidence interval. 
 
Table
 1 
 
 
 
Association of a common vitamin D-binding protein (DBP) 
polymorphism with inflammatory bowel disease 
 
Running Head: DBP SNP and IBD 
 
 
Jyrki J. Elorantaa,c,*, Christa Wengera,*, Jessica Mwinyia, Christian Hillera, Christoph 
Gublerb, Stephan R. Vavrickab,c, Michael Friedb,c, and Gerd A. Kullak-Ublicka,c, and 
the Swiss IBD Cohort Study Group 
 
aDepartment of Clinical Pharmacology and Toxicology and bDivision of Gastroenterology and 
Hepatology, University Hospital Zurich, Switzerland, and cZurich University Research Priority 
Programme "Integrative Human Physiology" (ZIHP), Switzerland 
 
*J.J.E. and C.W. contributed equally to this study. 
 
Correspondence and reprint requests to: 
Gerd A. Kullak-Ublick, MD 
Department of Clinical Pharmacology and Toxicology 
University Hospital Zurich 
Rämistrasse 100 
CH-8091 Zurich, Switzerland 
Phone: + 41 44 556 3150 
Fax: + 41 44 556 3152 
Email: gerd.kullak@usz.ch 
 
Funding: This study was financially supported by the Swiss National Science Foundation 
(SNF) grant 320030_120463 (G.A.K.-U. and J.J.E.) the Swiss IBD Cohort Study (SNF 
grant 33CSC0-108792), the Center of Clinical Research at the University Hospital Zurich 
(G.A.K.-U. and J.J.E.), and the Novartis Foundation for Biomedical Research (J.J.E.). 
*Revised manuscript with changes highlighted
 2 
Abstract 
 
Objective Inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis 
(UC), are multifactorial disorders, characterized by chronic inflammation of the intestine. A 
number of genetic components have been proposed to contribute to IBD pathogenesis. In 
this case-control study, we investigated the association between two common vitamin D-
binding protein (DBP) genetic variants and IBD susceptibility. These two single nucleotide 
polymorphisms in exon 11 of the DBP gene, at codons 416 (GAT>GAG; Asp>Glu) and 420 
(ACG>AAG; Thr>Lys), have previously been suggested to play roles in the etiology of other 
autoimmune diseases. 
 
Methods Using TaqMan SNP technology, we have genotyped 884 individuals (636 IBD 
cases and 248 non-IBD controls) for the two DBP variants. 
 
Results Upon statistical analysis, we observed that the DBP 420 variant Lys is less 
frequent in IBD cases than in non-IBD controls (allele frequencies, p=0.034; homozygous 
carrier genotype frequencies, p=0.006). This inverse association between the DBP 420 Lys 
and the disease remained significant, when non-IBD subjects were compared with UC 
(homozygous carrier genotype frequencies, p=0.022) or CD (homozygous carrier genotype 
frequencies, p=0.016) patients separately. While the DBP position 416 alone was not found 
to be significantly associated with IBD, the haplotype DBP_2, consisting of 416 Asp and 
420 Lys, was more frequent in the non-IBD population, particularly notably when compared 
to the UC group (OR 4.390). 
 
Conclusion Our study adds DBP to the list of potential genes that contribute to the complex 
genetic etiology of IBD, and further emphasizes the association between vitamin D 
homeostasis and intestinal inflammation. 
 
Key words: 
Inflammatory bowel disease, vitamin D-binding protein, Crohn’s disease, ulcerative colitis, 
vitamin D homeostasis 
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Introduction 
 
The biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 (vitamin D3) controls the 
serum calcium concentration and overall calcium homeostasis, and low vitamin D3 levels 
result in acceleration of bone turnover. Furthermore, vitamin D3 contributes to 
immunomodulation and possesses antiproliferative properties [1]. In the intestine, vitamin 
D3 has additional important functions, such as promotion of the integrity of mucosal tight 
junctions [2], enhancement of epithelial folate absorption [3], and activation of intestinal 
cytochrome P450 3A4 expression [4]. 
 
Vitamin D-binding protein (DBP) is a multifunctional glycosylated protein, encoded by the 
GC (gc-globulin = group-specific component) gene on chromosome 4 in humans [5-9, and 
references therein]. It belongs to the albumin multigene cluster family of proteins, together 
with -fetoprotein and albumin itself. DBP is synthesized predominantly in liver 
parenchymal cells, as a precursor form of 474 amino acids, which is processed to the 
mature form of 458 amino acids (~58 kDa). The primary structure of DBP contains 28 
cysteine residues, which can form multiple disulfide bonds. DBP primarily locates in 
circulating plasma at the concentration of ~5 M, but can also be found in ascitic and 
cerebrospinal fluids, and in cytoplasm of nucleated cells, as well as surface membranes of 
B and T lymphocytes. In plasma, DBP mediates vitamin D metabolite transport and fatty 
acid transport to target tissues. Additional reported functions of DBP include inhibition of 
actin polymerization and macrophage activation.  
 
The DBP gene in humans exists as three common variants, and over 100 rare variants [9]. 
The three major DBP isoforms are referred to as Gc1F (wild-type), Gc1S, and Gc2. All 
three isoforms exhibit comparable chemotactic activity [10], but the total levels of DBP in 
circulation appear to be determined by the Gc phenotype [11]. The isotypes are 
distinguished by distinct combinations of substitutions at amino acid positions 416 
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(Asp>Glu) and 420 (Lys>Thr). Relative to the wild-type Gc1F protein, the Gc1s is defined 
by containing the Asp416Glu polymorphism, and the Gc2 contains the Thr420Lys 
polymorphism. Enzymatic processing of the DBP O-linked carbohydrate to GalNac results 
in the transformation of the DBP molecules into the macrophage-activating factors (MAF). 
MAF is a lymphokine that primes macrophages, when required during the host defence 
responses in infectious and inflammatory diseases and against tumours [12]. Furthermore, 
MAF can induce macrophage cell death by enhancing caspase activity at sites of infection 
or inflammation [13]. 
 
Several studies have proposed a link between genetic variants of DBP and disease in 
humans. These include many conditions of suspected autoimmune etiology, such as 
Graves’ disease, diabetes, and osteoporosis [reviewed in 9]. Inflammatory bowel disease 
(IBD) is a condition characterized by recurrent inflammation of the intestinal mucosa, and is 
caused by deranged function of mucosal immune system in genetically susceptible 
subjects [reviewed in 14]. IBD etiology clearly involves a complex interaction of genetic, 
environmental, and immunomodulatory factors. Two major forms of IBD exist. In Crohn’s 
disease (CD), the entire gastrointestinal tract may be affected, although the most frequent 
site of inflammation is the ileum, whereas in ulcerative colitis (UC) the inflammation 
typically affects the colon. In CD pathogenesis, a strong genetic component has been 
suggested by the concordance of 63.6% in monozygotic twins, but only of 3.6% in dizygotic 
ones. In UC, the concordance of monozygotic twins is lower (6%), implying that genetic 
factors may play a somewhat smaller role in this disease [15]. IBD is more prevalent in 
northern Europe and North America, where less vitamin D is synthesized in the skin upon 
lower exposure to sunlight [16]. Vitamin D deficiency also frequently occurs in IBD patients, 
even when the disease itself may be in a state of remission [17]. 
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Genetic variants of the nuclear receptor for vitamin D3, VDR, the chief executor of vitamin 
D3 actions within cell nuclei, have previously been suggested to be associated with 
inflammatory bowel disease (IBD) [18,19]. Here, we have studied whether two common 
variants of the other important player in vitamin D homeostasis, DBP, are associated with 
IBD and its subtypes UC and CD. 
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Materials and methods 
 
Study subjects 
The study population was Swiss, and comprised of 248 healthy subjects and 636 IBD 
patients, from which 232 were diagnosed to suffer from UC and 404 from CD. The IBD 
subjects were recruited at the centers participating in the Swiss Inflammatory Bowel Disease 
Cohort Study (SIBDCS) [20]. For the IBD patients, the diagnosis of UC or CD was confirmed 
by the study investigators based on clinical presentation, endoscopic findings, and histology.  
Non-IBD controls were recruited from gastroenterological patients undergoing surveillance 
colonoscopy. History of colorectal cancer was employed as an exclusion criteria for both IBD 
patients and non-IBD control subjects. 
 
DNA extraction 
Genomic DNAs were extracted from either EDTA-blood or intestinal biopsies using the 
QIAamp DNA Mini Kit (QIAGEN, Hombrechtikon, Switzerland) or the TRIzol reagent 
(Invitrogen, Basel, Switzerland), respectively, according to the manufacturer’s instructions. 
 
Genotyping of DBP single nucleotide polymorphisms 
Genotyping of the two DBP SNPs was performed using TaqMan allelic discrimination 
assays. The cycling was performed on an 7900HT Fast Real-Time PCR system (Applied 
Biosystems, Rotkreuz, Switzerland) by using custom-made TaqMan SNP Genotyping 
Assays. The TaqMan primer and probe sequences were as follows: The Asp416Glu 
variant: Left primer, TGGCAGAGCGACTAAAAGCA; right primer, 
CTTGTTAACCAGCTTTGCCAGTTC; VIC-labelled probe AAATTGCCTGATGCCAC; FAM-
labelled probe TTGCCTGAGGCCAC. The Thr420Lys variant: Left primer, 
CGACTAAAAGCAAAATTGCCTGATG; right primer CTGAGTGCTTGTTAACCAGCTTTG; 
VIC-labelled probe CACCCACGGAACTG; FAM-labelled probe CACCCAAGGAACTG. All 
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fluorescent probes had a non-fluorescent quencher at 3’-end. The genomic DNAs were 
quantified with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) and diluted to a final concentration of 10 ng/µl. The amplification run 
conditions were: Once 50°C for 2 min, once 95°C for 10 min, 45 times 95°C for 15 sec and 
60°C for 1 min. 
 
Ethical considerations 
All subjects provided their written informed consent to be included in the study. Ethical 
approvals were obtained from the local medical ethical committees of all study sites 
involved in the Swiss IBD Cohort Study. 
 
Statistical analysis 
Statistical analysis was performed using the software packages SPSS 18 (SPSS Inc., 
Chicago, IL) and GraphPad Prism (GraphPad Software Inc., San Diego, CA). The Chi-
square test or Fisher’s exact test were used to determine associations between individual 
SNPs and subject phenotypes. The PHASE software was used to calculate the haplotypes 
in the DBP gene on the basis of a Bayesian interference algorithm [21]. Linkage 
disequilibrium (LD) was calculated using the r2 statistics. Calculations were performed using 
the software package Haploview (www.haploview.com).  
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Results 
 
 
Study population 
The study population was recruited at centers participating in the Swiss IBD Cohort study 
(SIBDCS). Detailed demographic data of the entire cohort consisting of 884 subjects is 
shown in Table 1. 
 
DBP sequence variability 
The two DBP variants selected for the study are single nucleotide substitutions. The 
genotype frequencies in all groups were in Hardy-Weinberg equilibrium. The obtained allele 
and genotype frequencies are given in Table 2. 
 
Genetic variation in the DBP gene and IBD 
The DBP variant 416 Glu was not found to be significantly associated with the diagnosis of 
IBD, although there was a tendency for this variant to be more common in the IBD 
population than in healthy subjects (Tables 2 and 3). The DBP variant 420 Lys, on the other 
hand, was more common in the healthy population than in the IBD cohort. The minor allele 
frequency was significantly (p=0.034) lower in the IBD population. The level of significance 
became much more notable (p=0.006), when the numbers of carriers of the wild-type 
genotype were compared to the numbers of homozygous SNP carrier in non-IBD and IBD 
populations. Upon subgrouping the IBD patients, the differences in the frequencies of the 
rarer 420 Lys variant remained significant for both UC (p=0.022) and CD (p=0.016). 
Similarly, when adjusted to age and gender, the p values remained significant. 
 
In addition to the two above-mentioned coding DBP SNPs, we also genotyped the study 
population for three DBP promoter SNPs, namely -1424, -944, and -39, previously studied in 
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the context of prostate cancer risk [22]. All the subjects in all subgroups of the current cohort, 
both IBD and non-IBD, were homozygous for the wild-type allele at these three positions 
(data not shown). 
 
DBP haplotypes and IBD 
All individuals, for whom genotype determination could be performed for both DBP variants 
under study were included in the haplotype prediction analysis. Thus, 185 non-IBD subjects, 
225 UC cases and 393 CD cases were included in this analysis. The predicted frequencies 
for all four possible DBP haplotypes are shown in Table 4. The haplotype DBP_2 containing 
the wild-type allele for the position 416 and the rarer allele for the position 420, was 
predicted to be significantly less frequent in the IBD population than in non-IBD subjects 
(p=0.0005) and this inverse association with the disease remained significant when either 
the UC (p=0.0003) or the CD (p=0.013) patients were compared with the non-IBD group 
separately (Table 5). The linkage equilibria between the variants at positions 416 and 420 of 
DBP were moderate (non-IBD controls r2=0.61; IBD cases r2=0.78). 
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Discussion 
 
The etiology of IBD is complex, and a wide range of factors, both genetic and 
environmental, are believed to play roles in IBD pathophysiology. Variants in more than 70 
genes have been identified that may potentially be associated with IBD [23,24]. Many of 
these encode genes that modulate immune responses and antimicrobial defence in the 
intestine, and are thus involved in maintaining the integrity of the intestinal wall epithelium 
[14,23]. Vitamin D metabolites have anti-inflammatory functions, and participate in the 
maintenance of tight junctions between intestinal epithelial cells [2]. While the other major 
player of vitamin D homeostasis, the vitamin D receptor VDR, has previously been 
genetically linked to IBD [18,19], we show here that a common genetic variant of DBP, the 
main transporter of vitamin D to its target tissues in the plasma, is significantly associated 
with IBD. This association is significant in both our UC and CD cohorts. The rarer Lys allele 
at position 420 appears to have a protective role against IBD, as it is more common in 
healthy subjects. The other DBP variant tested 416 Glu did not alone show a significant 
association with IBD, although it exhibited a tendency to be more frequent in IBD cases 
than control subjects, potentially thus acting as a factor contributing to the pathogenesis. 
The haplotype DBP_2, consisting of variants 416 Asp and 420 Lys, was significantly more 
frequent in the non-IBD population, more notably in comparison with the UC (OR 4.390). 
 
Low 25-hydroxyvitamin D3 levels are associated with insulin resistance and metabolic 
syndrome, and genetic variation in codon positions 416 and 420 has previously been 
proposed to be associated with diabetes [25,26], although this association remains 
somewhat controversial [27,28]. Furthermore, the DBP Lys allele at codon 420 has been 
associated with Graves’ disease in a Polish population [29], although in this case the lysine 
was in fact more common in the disease group. This points to potentially differing roles of 
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DBP in the etiologies of IBD and Graves’ disease, even if both represent autoimmune 
disorders. 
 
The exact functional consequences of the amino acid exchanges at positions 416 and 420 
of the DBP protein remain somewhat unclear. This region of the protein is located adjacent 
to the actin-binding domain of DBP (amino acids 350-403), but is more distant from the 
amino-terminal vitamin D-binding domain [30]. In the DBP form carrying the lysine in 
position 420, a major site for O-linked trisaccharide glycosylation is removed [31]. It will be 
of great interest to verify whether the efficiency of vitamin D transport by DBP is affected by 
this amino acid substitution, and in what manner. Given its inverse association with IBD 
reported here, it is perhaps paradoxical that the Gc2 isoform of DBP carrying the lysine in 
codon position 420 has been associated with lower plasma concentrations of vitamin D3 
metabolites than observed for the carriers of the other Gc alleles [11]. It has also been 
shown that the Gc2 isoform has reduced affinity to vitamin D metabolites [32]. We do not at 
this stage understand the exact mechanism by which a DBP isoform that exhibits lower 
affinity to vitamin D exerts a protective effect against IBD, as suggested by our current 
findings. It is conceivable that the reduced affinity could result in enhanced release of 
vitamin D from DBP to the intestinal target tissue that is susceptible to inflammation. 
 
Patients suffering from IBD are frequently on long-term treatment with vitamin D3, in 
addition to calcium, as a prophylaxis against osteoporosis and osteopenia [33]. It will be of 
interest to further explore whether the IBD-associated DBP variants are associated with 
altered clinical response to vitamin D3 supplementation. In conclusion, we have for the first 
time shown an association between a chief component of vitamin D metabolism, DBP, and 
diagnosis of IBD, further supporting the importance of vitamin D homeostasis in this chronic 
inflammatory disease. 
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